Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
FDA opts to nail down REMS plan for Sage's landmark postpartum depression drug, delays final decision
7 years ago
Pharma
Who are the best — and worst — among the major pharmas at developing drugs for the poor?
7 years ago
R&D
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
7 years ago
Deals
Stallergenes Greer's dust mite allergy drug clears pivotal study, edges closer to approval
7 years ago
R&D
As power shifts hands in Washington, a top analyst predicts an unavoidable war over rising drug prices
7 years ago
Pharma
Germany's Merck forges JV with Thiel's Palantir to harness data to attack cancer
7 years ago
Financing
Immunotherapy developer Enlivex uses Bioblast shell to reverse merge its way onto Nasdaq
7 years ago
Deals
FDA works to reduce dog testing in drug development
7 years ago
Pharma
Leo Pharma lines up an option to buy BridgeBio's PellePharm and its PhIII rare skin cancer drug
7 years ago
Pharma
Fortress Biotech sells brokerage firm following Reuters exposé; Tracon contends with another setback in brain cancer
7 years ago
News Briefing
Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot?
7 years ago
People
Novartis-backed Inflazome raises $46M for their clinical challenge to prove NLRP3 is a great anti-inflammatory target
7 years ago
Financing
Startups
Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers
7 years ago
Financing
China
Pfizer, Merck KGaA report their latest setback with checkpoint contender Bavencio
7 years ago
R&D
Tesaro stock soars on another report the PARP player is exploring a sale
7 years ago
Deals
Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but ...
7 years ago
R&D
Undeterred by exec exodus, Immunocore nabs $100M cash to co-develop preclinical asset with Roche
7 years ago
R&D
Discovery
Genfit plans US listing as NASH drugmakers race to the finish line
7 years ago
Financing
Pfizer preps a laundry list of drug price hikes for the New Year — let the political fireworks begin
7 years ago
Bioregnum
Opinion
While controversy over Brexit reaches full boil, a pharma trade group sees the upside in a draft deal
7 years ago
R&D
Pharma
Takeda family preps for a last-stand vote against Shire buyout; Eli Lilly reportedly shopping drug portfolio in China
7 years ago
News Briefing
Japanese billionaire Mikitani takes full control of Rakuten Aspyrian; HOX Therapeutics taps Karl Keegan as CEO
7 years ago
Peer Review
Sanofi teams with non-profit on a landmark new drug for sleeping sickness
7 years ago
R&D
Discovery
Eli Lilly partner Chi-Med sees shares tank as its newly approved cancer drug flunks PhIII lung cancer trial
7 years ago
R&D
First page
Previous page
994
995
996
997
998
999
1000
Next page
Last page